Medidata’s suite of technologies is supporting the advancement of Moderna’s mRNA-1273 clinical trials, including the Phase 3 trial, which is expected to enroll 30,000 participants. The Medidata and
NIAID is part of the National Institutes of Health, which is an agency of the US Department of Health and Human Services. The trial will target patients who
The study also met key secondary endpoints, significantly improving failure-free survival and patient-reported symptoms assessed by a validated chronic GvHD-specific score. These topline results build on positive data
The FDA has granted Priority Review for the NDA, which provides an expedited six month review, and has assigned a Prescription Drug User Fee Act (PDUFA) target action
Gilead is also provided with an exclusive option to purchase the remaining stake in Tizona for up to an additional $1.2bn. The deal is also comprised of an
Financial details of the agreement were not disclosed, but the terms were based on the timing of delivery and the volume of doses. “In the face of this
The companies have signed a collaboration agreement for the research, development, manufacturing and commercialisation of up to five messenger RNA (mRNA)-based vaccines and monoclonal antibodies (mAbs) to eliminate
OASIS-2 is a multicenter randomized, double-blind, placebo-controlled study comparing the efficacy and safety of mirikizumab to placebo and Cosentyx in patients with moderate to severe plaque psoriasis. The
The in-human study follows positive pre-clinical results for the treatment candidate, as well as successive approval of the investigational new drug application by the Korean Ministry of Food
BioAegis expects to recruit its first patient and begin the study shortly at Hospital Universitari Sant Joan de Reus in Tarragona, Spain. Clinical Protocol for Phase 2 Clinical
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.